Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Affiliation

Biomarker Discovery OMNI, Genentech Inc, South San Francisco, California, USA [Email] [Email]

Abstract

To unravel the hierarchy of cellular/molecular pathways in the disease tissue of early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes and treatment response/outcomes longitudinally.

Keywords

dmards (synthetic),early rheumatoid arthritis,inflammation,synovitis,

OUR Recent Articles